PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34088932-2	2021	S-Equol (SE), a selective estrogen receptor beta agonist, has been implicated as a neuroprotective and/or neurorestorative therapeutic for HIV-1 associated neurocognitive disorders (HAND); its therapeutic utility for motivational alterations, however, has yet to be systematically evaluated.	Equol	0-7	estrogen receptor 1	Homo sapiens	26-48	
34801689-4	2022	We aimed to elucidate the mechanism for ER-independent actions of equol.	Equol	66-71	estrogen receptor 1	Homo sapiens	40-42	
34801689-11	2022	Together, these results suggest that equol may have a dual effect on ER-positive cancer cells, acting with, antiproliferative activity through PAPD5 and exhibiting proliferative activity via ERalpha and the former could be associated with miR-320a.	Equol	37-42	estrogen receptor 1	Homo sapiens	191-198	
34681876-5	2021	Finally, a brief history of cosmetics to nutraceuticals is covered plus the characteristics of phytoestrogens, resveratrol and equol on: (g) estrogen receptor binding, (h) topical and oral dosing, and (i) in vitro, molecular mechanisms and select clinical evidence, where both phytoestrogens (resveratrol and equol) demonstrate promising applications to improve skin health is presented along with future directions of nutraceuticals.	Equol	127-132	estrogen receptor 1	Homo sapiens	141-158	
34088932-2	2021	S-Equol (SE), a selective estrogen receptor beta agonist, has been implicated as a neuroprotective and/or neurorestorative therapeutic for HIV-1 associated neurocognitive disorders (HAND); its therapeutic utility for motivational alterations, however, has yet to be systematically evaluated.	Equol	9-11	estrogen receptor 1	Homo sapiens	26-48	
31623342-11	2019	The mechanism underlying S-equol neuroprotection might involve ERalpha-mediated pathways.	Equol	25-32	estrogen receptor 1	Homo sapiens	63-70	
31623342-0	2019	Equol Pretreatment Protection of SH-SY5Y Cells against Abeta (25-35)-Induced Cytotoxicity and Cell-Cycle Reentry via Sustaining Estrogen Receptor Alpha Expression.	Equol	0-5	estrogen receptor 1	Homo sapiens	128-151	
31623342-9	2019	Treatment with the ER antagonist, ICI-182,780 (1 muM), completely blocked the effects of S-equol and 17beta-estradiol on cell viability, ERalpha, and ERK1/2 after Abeta (25-35) exposure.	Equol	89-96	estrogen receptor 1	Homo sapiens	137-144	
32492805-4	2020	Equol is one of the most active isoflavone metabolites, produced by intestinal bacteria, and acts as a selective estrogen receptor modulator.	Equol	0-5	estrogen receptor 1	Homo sapiens	113-130	
28985044-8	2017	Although (S)-equol favors binding to human estrogen receptor (hER) beta over hERalpha, (-)-5-hydroxy-equol showed the opposite preference.	Equol	9-18	estrogen receptor 1	Homo sapiens	43-85	
30889096-1	2019	OBJECTIVE: PhytoSERM is a formulation of genistein, daidzein, and S-equol that has an 83-fold selective affinity for estrogen receptor-beta (ERbeta); and may enhance neuron function and estrogenic mechanisms in the brain without having peripheral estrogenic activity.	Equol	66-73	estrogen receptor 1	Homo sapiens	117-139	
30889096-1	2019	OBJECTIVE: PhytoSERM is a formulation of genistein, daidzein, and S-equol that has an 83-fold selective affinity for estrogen receptor-beta (ERbeta); and may enhance neuron function and estrogenic mechanisms in the brain without having peripheral estrogenic activity.	Equol	66-73	estrogen receptor 1	Homo sapiens	141-147	
23088310-4	2012	Using L-buthionine (S,R)-sulfoximine (BSO) to induce oxidative stress in human FRDA fibroblasts, we determine the potency and efficacy of the soy-derived ERbeta agonist S-equol and its ERalpha-preferring enantiomer, R-equol in vitro on cell viability and ROS accumulation.	Equol	169-176	estrogen receptor 1	Homo sapiens	154-160	
28598847-3	2017	To assess whether an ERbeta agonist could improve mitochondrial function in actual AD subjects, we administered S-equol (10 mg twice daily) to 15 women with AD and determined the platelet mitochondria cytochrome oxidase (COX) activity before initiating S-equol (lead-in), after two weeks of S-equol (active treatment), and two weeks after stopping S-equol (wash-out).	Equol	112-119	estrogen receptor 1	Homo sapiens	21-27	
21861338-8	2011	CONCLUSION: R-(+) equol and S-(-) equol inhibited motility and invasion in PC3 and DU145 cells, while the most strong effect was observed in PC3 cells by R-(+) equol, which might regulated by the activation of estrogen receptor-alpha.	Equol	31-39	estrogen receptor 1	Homo sapiens	210-233	
16884174-1	2006	The soy isoflavones genistein and daidzein, as well as the daidzein metabolite equol, have structural similarities to mammalian estrogens and bind with varying affinity to both known subtypes of the estrogen receptor.	Equol	79-84	estrogen receptor 1	Homo sapiens	199-216	
19427779-1	2010	The aim of this study was to determine whether the extracellular-signal-regulated kinase 1/2 (ERK1/2) pathway is involved in genistein- and equol-induced cell proliferation and estrogen receptor (ER) alpha transactivation.	Equol	140-145	estrogen receptor 1	Homo sapiens	177-205	
19427779-3	2010	Genistein- and equol-induced cell proliferation and S-phase entry were blocked by the ERalpha antagonists 4-hydroxytamoxifen and ICI 182,780 and by the mitogen-activated protein kinase 1/2 inhibitor U0126.	Equol	15-20	estrogen receptor 1	Homo sapiens	86-93	
15151933-12	2004	In conclusion, equol is a weak estrogen with modest effects on endpoints regulated by estrogen receptor alpha when present at serum levels seen in rodents fed soy-based diets, but quantities present in humans may not be sufficient to induce estrogenic effects, although additive effects of equol with other phytoestrogens may occur.	Equol	15-20	estrogen receptor 1	Homo sapiens	86-109	
15018930-6	2004	In binding assays, S-equol has a high binding affinity, preferential for ERbeta (K(i)[ERbeta]=16 nM; beta/alpha=13 fold), that is comparable to that of genistein (K(i)[ERbeta]=6.7 nM; beta/alpha=16), whereas R-equol binds more weakly and with a preference for ERalpha (K(i)[ERalpha]=50 nM; beta/alpha=0.29).	Equol	20-26	estrogen receptor 1	Homo sapiens	260-267	
15018930-6	2004	In binding assays, S-equol has a high binding affinity, preferential for ERbeta (K(i)[ERbeta]=16 nM; beta/alpha=13 fold), that is comparable to that of genistein (K(i)[ERbeta]=6.7 nM; beta/alpha=16), whereas R-equol binds more weakly and with a preference for ERalpha (K(i)[ERalpha]=50 nM; beta/alpha=0.29).	Equol	20-26	estrogen receptor 1	Homo sapiens	274-281	
14664520-10	2003	The endogenous hormone 17beta-estradiol as well as coumestrol and daidzein metabolite equol activate the binding of ERbeta to ERE only slightly more effectively than the binding of ERalpha to ERE.	Equol	86-91	estrogen receptor 1	Homo sapiens	181-188